07:00 , May 30, 2005 |  BC Week In Review  |  Company News

Prometic management update

ProMetic Life Sciences Inc. (TSE:PLI), Montreal, Quebec   Business: Dermatology, Generics, Supply/service   Hired: Vincent Taillefer as VP of corporate development, formerly VP of finance at Angiogene Inc.   Promoted: Stephane Archambault to VP of...
07:00 , May 10, 2004 |  BC Week In Review  |  Company News

Clinigenetics SA management update

Clinigenetics SA , Nimes, France   Business: Cardiovascular, Metabolic   Hired: Jeannette Fareh as head of pharmacological and preclinical research, formerly research director at Angiogene Inc.  ...
08:00 , Mar 17, 2003 |  BioCentury  |  Emerging Company Profile

Corporate Profile

MaxCyte Corp. Rockville, Md. Technology: Flow electroporation for non-viral gene and drug delivery and drug discovery Disease focus: Cancer, cardiovascular Clinical Status: Phase I Founded: 1999 by Douglas Doerfler and John Holaday Corporate partners: Angiogene...
08:00 , Mar 17, 2003 |  BioCentury  |  Emerging Company Profile

MaxCyte: Power loading

As viral vectors used in gene therapy have raised safety concerns, their elimination may be key to progress in the field. MaxCyte Corp. believes that one way to overcome this technical and regulatory hurdle is...
07:00 , Jul 15, 2002 |  BC Week In Review  |  Company News

Angiogene, EntreMed Inc. (ENMD) deal

ENMD's majority-owned subsidiary MaxCyte Inc. partnered with Angiogene to research and develop a non-viral therapy to treat congestive heart failure (CHF) caused by myocardial infarction. Angiogene will use MaxCyte's cell loading system with its AngioCell...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

Oliglow: Began Phase I/II trial

Angiogene Inc. , Montreal, Quebec   Product: Oliglow   Business: Cardiovascular   Therapeutic category: Cell proliferation   Target: Arterial smooth muscle cells   Description: DNA beta-emitting isotope complex   Indication: Prevent restenosis   Endpoint: Safety...
08:00 , Nov 19, 2001 |  BC Week In Review  |  Clinical News

Angiogene preclinical data

Angiogene said pigs receiving the Oliglow loaded stent had reduced in-stent restenosis and improvements in vessel lumen size ranging from 33% in a low dose group to 54% in a high dose group. Biocompatibles International...
08:00 , Nov 9, 1998 |  BioCentury  |  Emerging Company Profile

Angiogene Inc.

Angiogene Inc. Montreal, Quebec Technology: Antiproliferative therapeutics Disease focus: Restenosis and other proliferative disorders Clinical status: Preclinical Founded: 1995 by Guy Leclerc and Francois Bergeron Corporate partners: None University collaborators: Centre Hospitalier de l'Universite de...
08:00 , Nov 9, 1998 |  BioCentury  |  Emerging Company Profile

Angiogene: Antiproliferative radiation

Angiogene: Antiproliferative radiation Radiation treatment has long been synonymous with cell killing. But Angiogene Inc. is taking a different approach. The company specializes in delivering radioisotopes within the nuclei of proliferating cells, not to kill...
08:00 , Nov 2, 1998 |  BC Week In Review  |  Clinical News

Angiogene regulatory update

Angiogene received U.S. Patent No. 5,821,354 covering the method of preparation and the coronary delivery of a radiolabeled oligonucleotide at a dilation site of an artery to prevent uncontrolled cellular proliferation and restenosis. Angiogene Inc.,...